Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Operating Expenses (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Other Operating Expenses data on record, last reported at $10.9 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 121.82% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $30.7 million, up 139.23%, while the annual FY2025 figure was $30.7 million, 139.23% up from the prior year.
  • Other Operating Expenses reached $10.9 million in Q4 2025 per TARS's latest filing, up from $8.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $10.9 million in Q4 2025 and bottomed at -$24000.0 in Q4 2021.
  • Average Other Operating Expenses over 5 years is $3.9 million, with a median of $3.0 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: tumbled 99.07% in 2021, then soared 41883.33% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at -$24000.0 in 2021, then skyrocketed by 41883.33% to $10.0 million in 2022, then plummeted by 87.87% to $1.2 million in 2023, then surged by 305.1% to $4.9 million in 2024, then soared by 121.82% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $10.9 million in Q4 2025, $8.3 million in Q3 2025, and $6.2 million in Q2 2025.